SCHEMBL4234064

SCHEMBL4234064

CCOC(=O)C[C@H]1CC[C@H](CN(CC)c2ncc(C(F)(F)F)cc2C=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
CCRL2 O00421 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
DGAT1 O75907 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4231284 1.00 KDM4E (0.41) KDM4ECCRL2L3MBTL1ALDH1A1HPGD
SCHEMBL14470738 1.00 KDM4E (0.41) KDM4ECCRL2L3MBTL1ALDH1A1HPGD
SCHEMBL4224281 0.87 KDM4E (0.41) KDM4ECCRL2L3MBTL1ALDH1A1HPGD
SCHEMBL4228266 0.87 KDM4E (0.41) KDM4ECCRL2L3MBTL1ALDH1A1HPGD
SCHEMBL4228105 0.86 KDM4E (0.41) KDM4ECCRL2L3MBTL1ALDH1A1HPGD
SCHEMBL4228109 0.86 KDM4E (0.41) KDM4ECCRL2L3MBTL1ALDH1A1HPGD
SCHEMBL4218202 0.85 CYP1A2 (0.40) KDM4ECCRL2ALDH1A1JAK2JAK1
SCHEMBL4219459 0.85 CYP1A2 (0.40) KDM4ECCRL2ALDH1A1JAK2JAK1
SCHEMBL4228333 0.85 TRPM8 (0.41) L3MBTL1ALDH1A1KMT2ALMNATRPM8
SCHEMBL3033676 0.82 CCRL2 (0.41) KDM4ECCRL2L3MBTL1ALDH1A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075968-A1 CETP inhibitors SAKAKI JUNICHI 2009-03-19 US disclosed
US-20090075968-A1 CETP inhibitors SAKAKI JUNICHI 2009-03-19 US disclosed
US-20090075968-A1 CETP inhibitors SAKAKI JUNICHI 2009-03-19 US disclosed
EP-1968941-A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) Novartis AG (CH) 2008-09-17 EP disclosed
WO-2007073934-A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) NOVARTIS AG (CH) 2007-07-05 WO disclosed
WO-2007073934-A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) NOVARTIS AG (CH) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075968-A1 CETP inhibitors CETP, PCSK9, MTTP KDM4E 1219/4885CCRL2 3620/4885L3MBTL1 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.